Treatment of Non-infectious Disease — Pharmacological, Surgical, Lifestyle and Emerging Therapies
Treating non-infectious disease means understanding what is broken at the molecular, cellular, or organ level — and finding the most precise, effective, and safe way to fix it. Every treatment approach in this lesson traces directly back to the disease mechanisms you studied in IQ2.
Download this lesson's worksheet
Use the PDF for classwork, homework or revision. It includes key ideas, activities, questions, an extend task and success-criteria proof.
Sensory Disorders
If You Know What Causes a Disease, Can You Always Treat It?
Cystic fibrosis was first described in 1938. The CFTR gene was identified in 1989. Despite knowing the exact genetic cause for 35 years, a truly effective treatment (Trikafta — a CFTR modulator) only reached Australian patients in 2022. The mechanism was understood decades before the treatment existed.
Type 2 diabetes, by contrast, can be dramatically improved by lifestyle modification — weight loss, dietary change, and physical activity — without any drug, simply by reducing the metabolic overload that drives insulin resistance. The treatment in this case requires no molecular knowledge of insulin signalling, just intervention at the behavioural level.
Before reading on:
Q1: What does the cystic fibrosis story suggest about the relationship between understanding a disease mechanism and being able to treat it? What types of treatment can work at the molecular level?
Q2: For a disease like Type 2 diabetes, which has both genetic and lifestyle causes, what are the advantages and disadvantages of treating it with: (a) a drug; (b) lifestyle modification?
Know
- The four main categories of treatment: pharmacological, surgical, lifestyle, and emerging therapies
- Specific examples of each treatment type for diseases studied in IQ2
- How CFTR modulators treat cystic fibrosis at the molecular level
- How lifestyle modification can achieve T2D remission
Understand
- Why understanding disease mechanism directly enables rational drug design
- Why targeted therapies have fewer side effects than cytotoxic chemotherapy
- How immunotherapy works differently from conventional cancer treatment
- Why lifestyle modification is mechanistically the most direct treatment for T2D
Can Do
- Match treatments to specific diseases and explain the mechanism of each
- Evaluate the advantages and limitations of different treatment approaches
- Connect treatment mechanisms back to the disease mechanisms studied in IQ2
- Distinguish between treating symptoms, managing progression, and addressing root cause
Connect this concept back to the broader homeostasis and disease framework you have built across the course.
The Treatment Framework — From Root Cause to Symptom Management
Try this: Select a disease (cancer, Type 2 diabetes, or hypertension), then choose the most appropriate first step in management from the options provided.
This simulation tests whether you can apply the treatment hierarchy: lifestyle and least invasive options come first for early-stage disease.
Treatment pathways follow a hierarchy from least invasive to most invasive. For early-stage metabolic disease, lifestyle modification is first-line. For localised cancer, surgical resection is typically first-line. Understanding why one treatment precedes another is critical for HSC evaluation questions.
Every treatment for non-infectious disease can be categorised by where it intervenes in the disease pathway. Some treatments address the root cause directly (CFTR modulators fix the dysfunctional protein in CF). Some slow disease progression (statins slow atherosclerosis). Some manage symptoms without altering the underlying process (pain relief for cancer). The most desirable treatments address root causes — but they are often the hardest to develop.
Treatment approaches for non-infectious disease
Treatment hierarchy from prevention to cure
| Level of intervention | What it does | Example | Limitation |
|---|---|---|---|
| Root cause | Corrects the fundamental molecular or cellular defect driving disease | CFTR modulators in CF — restore CFTR protein function | Requires detailed molecular knowledge; technically difficult; not always possible |
| Mechanism | Interrupts a key step in the disease pathway without correcting the root cause | Insulin therapy in T1D — replaces missing insulin; BRAF inhibitors in melanoma — inhibit the oncogenic protein | Does not cure the underlying condition; long-term management required |
| Progression | Slows the rate at which disease worsens | Statins reducing LDL to slow atherosclerosis; ACE inhibitors reducing blood pressure to slow kidney damage in diabetes | Disease continues to progress, just more slowly; patient still needs ongoing treatment |
| Symptoms | Relieves symptoms without affecting the disease process | Analgesics for cancer pain; bronchodilators for COPD symptoms | No impact on disease trajectory — disease continues unchecked |
Pharmacological Treatments — Drugs That Target Disease Mechanisms
Try this: Click a treatment name, then click the matching description. Match all five treatments and check your answers.
Each treatment category has a distinct mechanism — understanding these distinctions is what earns Band 5–6 marks.
Each treatment category has a distinct mechanism of action. Pharmacological treatments target specific molecules. Surgical treatments physically remove or repair diseased tissue. Lifestyle modification addresses root behavioural causes. Gene therapy aims to correct genetic defects at the DNA level.
Pharmacological treatments work by interacting with specific molecular targets — receptors, enzymes, ion channels, or signalling proteins — to either restore a function that is lost or inhibit a process that is overactive. The more precisely a drug targets the disease-causing mechanism, the fewer off-target side effects it produces.
Insulin therapy — Type 1 diabetes (connecting to L07)
In Type 1 diabetes, autoimmune destruction of beta cells eliminates insulin production. The treatment replaces what is missing: exogenous insulin is injected or delivered via a continuous subcutaneous pump. Modern insulins are recombinant human insulin (produced by genetically modified bacteria — a biotechnology application you will revisit in L17). Rapid-acting analogues (lispro, aspart) are taken with meals to manage post-meal glucose spikes; long-acting analogues (glargine, detemir) provide background insulin coverage. Closed-loop insulin pump systems now use continuous glucose monitoring to automatically adjust insulin delivery — approaching artificial pancreas function.
Statins — cardiovascular disease (connecting to L09)
Statins (e.g. atorvastatin, rosuvastatin) inhibit HMG-CoA reductase — the rate-limiting enzyme in the liver's cholesterol synthesis pathway. Blocking this enzyme reduces hepatic cholesterol production → liver upregulates LDL receptors to capture more LDL from the blood → blood LDL concentration falls → less LDL available to infiltrate arterial walls → slower atherosclerotic plaque formation. This is mechanism-level intervention: statins do not reverse existing plaques, but reduce the rate of new plaque formation. They also have anti-inflammatory effects in arterial walls independent of their LDL-lowering action.
CFTR modulators — cystic fibrosis (connecting to L07)
CFTR modulators are the first treatments to target the root cause of cystic fibrosis at the molecular level. There are two classes: correctors (e.g. elexacaftor, lumacaftor) help the misfolded F508del CFTR protein fold correctly and reach the cell membrane; potentiators (e.g. ivacaftor) hold the CFTR channel open for longer once it reaches the membrane. Trikafta (elexacaftor-tezacaftor-ivacaftor — two correctors plus a potentiator) is effective in ~90% of CF patients with the F508del mutation. Clinical impact: lung function improved by 10–14 percentage points; hospitalisation rates fell dramatically; life expectancy is expected to increase by decades. This is the clearest example of mechanistic understanding of a genetic disease directly producing a transformative treatment.
Targeted therapy in cancer — BRAF inhibitors (connecting to L10)
Approximately 50% of melanomas carry the BRAF V600E oncogene mutation (a constitutively active BRAF kinase). BRAF inhibitors (vemurafenib, dabrafenib) specifically bind and inhibit the mutant BRAF V600E protein — blocking the constitutive proliferation signal it generates. Because the drug targets a cancer-specific mutation rather than a normal cellular process, it preferentially kills BRAF V600E-mutant cancer cells while sparing most normal cells. Contrast with conventional chemotherapy (cytotoxic drugs that kill all rapidly dividing cells — cancer and healthy alike, producing the characteristic side effects of hair loss, nausea, immunosuppression).
Immune checkpoint inhibitors (connecting to L10)
Advanced cancers often evade immune attack by expressing PD-L1 on their surface, which binds the PD-1 receptor on cytotoxic T cells and switches them off. Pembrolizumab and nivolumab are antibodies that block this PD-1/PD-L1 interaction — releasing the immune system's brake on T cell activity. With PD-1 blocked, T cells can recognise and kill cancer cells that were previously invisible to immune surveillance. Unlike chemotherapy (which kills rapidly dividing cells directly), immunotherapy works by restoring immune function — the immune system then kills the cancer. This produces durable responses in some patients because the immune system can establish memory and maintain long-term surveillance.
ACE inhibitors and ARBs — cardiovascular disease and diabetic nephropathy
ACE inhibitors (e.g. ramipril, perindopril) block angiotensin-converting enzyme, preventing the production of angiotensin II — the vasoconstrictor that drives blood pressure up via the RAAS pathway (covered in L04). Lower angiotensin II → less vasoconstriction → lower blood pressure → reduced mechanical stress on arterial walls (slowing atherosclerosis) and reduced pressure in glomerular capillaries (protecting kidneys from diabetic nephropathy). These drugs treat multiple mechanisms simultaneously: hypertension, heart failure, and kidney protection in diabetes.
Surgical Treatments and Lifestyle Modification
Some non-infectious diseases require structural correction that drugs cannot provide. Others — particularly Type 2 diabetes and cardiovascular disease — respond more powerfully to lifestyle modification than to any single drug, because lifestyle addresses the primary metabolic drivers of the disease rather than compensating for their effects.
Surgical interventions for cardiovascular disease
Coronary angioplasty and stenting: A catheter with an inflatable balloon is inserted into a blocked coronary artery via the femoral artery. The balloon is inflated to compress the atherosclerotic plaque and widen the lumen. A metal mesh stent is then deployed to hold the artery open permanently. This restores blood flow to ischaemic heart muscle. Drug-eluting stents (coated with anti-proliferative drugs) reduce restenosis — scar tissue re-narrowing the stent — by inhibiting smooth muscle cell proliferation at the stent site.
Coronary artery bypass grafting (CABG): In severe multi-vessel disease where angioplasty is insufficient, a surgeon grafts a section of vein (usually from the leg) or artery (internal mammary) around the blocked coronary segment, creating a new route for blood to reach the heart muscle. This is major open-heart surgery — reserved for patients with extensive blockages or failed angioplasty.
Lifestyle modification — Type 2 diabetes remission
Type 2 diabetes can enter full remission (blood glucose returning to the non-diabetic range without medication) in patients who achieve significant weight loss — typically 10–15 kg. The mechanism: excess visceral adipose tissue produces inflammatory cytokines (adipokines) that impair insulin receptor signalling in liver, muscle, and fat cells. Weight loss reduces visceral fat → inflammatory signalling falls → insulin receptor sensitivity is restored → beta cells, which were not destroyed (unlike T1D) but were overworked and functionally exhausted, can recover their normal secretory capacity.
The DiRECT trial (UK, 2018) demonstrated that structured dietary weight management achieved remission in 46% of patients at 12 months. At 2 years, 36% remained in remission. This is the most powerful treatment for T2D in patients who can achieve sufficient weight loss — more effective per kilogram lost than any currently approved drug. However, remission is not a cure — the underlying genetic predisposition remains, and disease recurs with weight regain.
Physical activity as treatment
Regular moderate-intensity physical activity independently improves insulin sensitivity in skeletal muscle (through GLUT4 transporter upregulation — contracting muscle can take up glucose via an insulin-independent pathway), reduces cardiovascular risk (lowering blood pressure, improving lipid profile, reducing inflammatory markers), and has neuroprotective effects relevant to dementia prevention. Exercise is classified as a 'polypharmacy equivalent' in some guidelines — it benefits cardiovascular disease, Type 2 diabetes, depression, osteoporosis, and cancer risk simultaneously through multiple mechanisms.
Emerging Therapies — At the Frontier of Non-infectious Disease Treatment
Emerging therapies represent the direct application of molecular biology and genetic knowledge to disease treatment — the logical endpoint of the IQ2 content you have already studied. Understanding these therapies requires connecting what you know about gene mutations, protein function, and cell biology to specific therapeutic strategies.
CAR-T Cell Therapy (Cancer)
A patient's own T cells are extracted and genetically engineered in the laboratory to express a Chimeric Antigen Receptor (CAR) — an artificial receptor designed to recognise a specific protein on the surface of cancer cells (e.g. CD19 on B-cell leukaemia). The modified cells are expanded in culture and reinfused. The engineered T cells seek out and kill cancer cells expressing the target antigen. CAR-T has produced durable complete remissions in patients with relapsed/refractory leukaemia and lymphoma who had no other options. Approved in Australia for certain blood cancers.
Antisense Oligonucleotides (Huntington's Disease)
Antisense oligonucleotides (ASOs) are short synthetic DNA/RNA strands that bind to the mutant HTT mRNA and trigger its degradation — reducing the production of toxic polyQ huntingtin protein before it can accumulate in neurons. Clinical trials (IONIS-HTTRx, now tominersen) demonstrated significant reductions in mutant huntingtin in cerebrospinal fluid. This approach targets the disease at the mRNA level — downstream of the gene mutation but upstream of the toxic protein. Currently in Phase 3 trials for Huntington's disease.
CRISPR Gene Editing (CF, Sickle Cell, Cancer)
CRISPR-Cas9 allows precise editing of DNA sequences — in principle, correcting the F508del mutation in CFTR or other disease-causing mutations at the source. In 2023, Casgevy — the world's first approved CRISPR therapy — was approved for sickle cell disease and beta-thalassaemia. For CF, CRISPR editing of lung stem cells to correct CFTR mutations is in early development. For cancer, CRISPR is being used to engineer tumour-infiltrating lymphocytes with enhanced cancer-killing activity. This technology will be covered in more detail in L16 (IQ4 — Prevention).
GLP-1 Receptor Agonists (T2D and Obesity)
GLP-1 agonists (semaglutide — brand name Ozempic/Wegovy; liraglutide — Victoza/Saxenda) mimic the gut hormone glucagon-like peptide-1, which stimulates insulin secretion from beta cells in a glucose-dependent manner, suppresses glucagon, delays gastric emptying, and reduces appetite centrally. Originally developed for Type 2 diabetes, semaglutide also produces 15–17% body weight reduction in trials — the most effective non-surgical weight loss treatment ever approved — leading to its use in obesity treatment and driving T2D remission through weight loss. As of 2024, trials also show cardiovascular mortality benefit independent of glucose lowering.
How a Molecular Understanding of CF Finally Produced a Transformative Treatment
For most of the 20th century, treatment for cystic fibrosis was purely symptomatic — physiotherapy to clear mucus, antibiotics for infections, nutritional supplementation for malabsorption. Life expectancy for CF patients was measured in years to early decades. None of these treatments addressed the root cause: the dysfunctional CFTR protein.
The identification of the CFTR gene in 1989 began a 30-year journey toward targeting the protein directly. The first CFTR potentiator, ivacaftor (Kalydeco), was approved in 2012 — but it only worked for the rare G551D mutation (~4% of CF patients), not for the common F508del mutation (~70%). The challenge with F508del was that the protein misfolded before reaching the membrane — a corrector was needed to stabilise its folding, plus a potentiator to keep the channel open once it arrived.
Trikafta — combining two correctors (elexacaftor and tezacaftor) with the potentiator ivacaftor — was approved by the US FDA in 2019. In clinical trials, it improved lung function by approximately 14 percentage points (a massive improvement for a lung disease measured in single-digit annual declines), reduced pulmonary exacerbations by 63%, and transformed quality of life. The TGA approved it in Australia in 2021 and the PBS listed it in 2022. The CF community described the day of PBS listing as a turning point in the history of the disease. Children starting Trikafta today may never need a lung transplant — something that would have been unimaginable for most CF patients 10 years ago.
Priority Misconceptions — Treatment of Non-infectious Disease
"Treating a disease means curing it." — Most treatments for non-infectious disease manage the disease rather than curing it. Insulin therapy manages T1D but does not restore beta cells. Statins slow atherosclerosis but do not reverse existing plaques. CFTR modulators restore CFTR function but do not correct the underlying genetic mutation (which persists in every cell). Distinguishing between management, remission, and cure is important — and examiners test this distinction.
"Chemotherapy targets cancer cells specifically." — Cytotoxic chemotherapy kills all rapidly dividing cells — cancer cells and healthy cells alike (hair follicles, bone marrow, gut lining). This non-specificity causes the classic side effects. Targeted therapy (e.g. BRAF inhibitors, CFTR modulators, imatinib for CML) is designed to interact with specific disease-causing molecular targets, sparing normal cells — a fundamentally different approach with a more favourable side-effect profile.
"Type 2 diabetes remission = cure." — Remission means blood glucose returns to the non-diabetic range without medication — but the underlying genetic predisposition to insulin resistance remains. Weight regain typically causes recurrence. Remission is a reversible metabolic state, not a permanent cure. The distinction matters: patients in remission still require monitoring and should maintain the lifestyle changes that achieved remission.
"Lifestyle modification is a 'soft' treatment — drugs are more scientific." — The DiRECT trial demonstrated that structured dietary weight management achieved T2D remission in 46% of patients at 12 months — substantially more effective than any currently approved T2D drug at producing remission. Lifestyle modification works through understood biological mechanisms (visceral fat reduction → adipokine normalisation → insulin receptor sensitisation → beta cell recovery). It is a mechanistically justified treatment — not less 'scientific' than pharmacotherapy.
"Immunotherapy works by boosting the immune system generally." — Immune checkpoint inhibitors (pembrolizumab, nivolumab) do not generally 'boost' the immune system. They specifically block the PD-1/PD-L1 interaction that cancer cells exploit to switch off cytotoxic T cells — releasing a specific inhibitory brake on a specific subset of immune cells. This is targeted molecular manipulation of one immune signalling pathway, not a generalised immune stimulation.
Image Slot 1: Diagram of CFTR modulator mechanism — normal CFTR protein reaching membrane vs F508del misfolded protein being degraded. Show corrector drug stabilising F508del folding → protein reaches membrane → potentiator drug holds channel open → Cl⁻ secretion restored → water follows → mucus hydrated. Annotate the two drug actions (corrector = folding; potentiator = gating).
Image Slot 2: Comparison of chemotherapy vs targeted therapy vs immunotherapy mechanisms. Chemotherapy: kills all rapidly dividing cells (cancer + healthy cells, with side effects labelled). Targeted therapy: drug binds specific mutant protein on cancer cell only. Immunotherapy: PD-1/PD-L1 blockade releasing T cell to kill cancer cell. Three parallel diagrams with clear labelling of specificity differences.